NCT04562129 2026-04-01
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
Medicenna Therapeutics, Inc.